Diaceutics stock price target lowered to 185p by RBC on FX headwinds

RBC has reduced its price target for Diaceutics (LON:DXRX) from 195p to 185p, citing unfavorable foreign exchange impacts on revenue estimates, yet maintains an Outperform rating given the new target still implies over 50% upside from current levels. Despite shares falling over 20% since February, the firm highlights strong commercial momentum, including a 93% increase in Total Contract Value, and forecasts a return to earnings profitability this year with £39.5m in full-year revenue and a 17.8% adjusted EBITDA margin. While RBC anticipates significant long-term upside, up to six times in an M&A scenario, it notes the need for improvement in the multi-year order book.

Analysis

RBC has adjusted its price target for Diaceutics PLC (DXRX) to 185p from 195p, a move driven by unfavorable foreign exchange movements which negatively impacted revenue estimates by 4-5%, rather than a deterioration in core business operations. Despite this reduction, the firm maintains its Outperform rating, noting the new target implies over 50% upside from current levels, particularly after the stock has declined more than 20% since its February high. The company's underlying commercial momentum appears strong, evidenced by a 93% year-over-year increase in Total Contract Value to £18.7m in the first four months of the year and reported revenue growth of 35% YoY for the same period. RBC forecasts a return to earnings profitability in the current year, projecting full-year revenue of £39.5m (a 26% increase at constant currency) and an adjusted EBITDA margin of 17.8%. A key area for investor scrutiny is the multi-year order book, which reportedly declined at the end of 2024, contrasting with strong one-year visibility and creating a potential risk to long-term growth sustainability. RBC also highlights substantial long-term potential, with valuations suggesting up to a six-fold increase in an M&A scenario.

Key Decisions for Investors

• Investors could consider the recent share price weakness as a tactical buying opportunity, given the price target downgrade was driven by technical FX factors rather than fundamental business weakness.
• The upcoming H1 trading update in July is a key catalyst to watch for confirmation of the projected 32% constant-currency revenue growth and the company's trajectory back to profitability.
• While near-term growth metrics are robust, it is critical to monitor management's commentary regarding the multi-year order book to assess the durability of long-term revenue streams.
• For those with a long-term horizon, the potential for significant upside through margin expansion or a future M&A event warrants consideration, though this should be weighed against the noted decline in the multi-year order book.